Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback